CUREVERSE
Latest round
- Series B
Last raised
- Jan 2025
Total raised
- $17M
Investors
- 7
About CUREVERSE
Based in Seoul, South Korea, CUREVERSE Inc. was founded in 2021 and is headquartered at the Korea Institute of Science and Technology (KIST). The company specializes in discovering and developing novel small-molecule drug candidates targeting difficult-to-treat diseases. Guided by its proprietary “Right Structure” philosophy, Cureverse aims to address the root causes of diseases rather than merely treating symptoms. Its pipeline includes therapies for Alzheimer's disease, multiple sclerosis, cancer, fibrosis, and metabolic and inflammatory disorders. The company focuses on the discovery and development of small-molecule therapeutics for neurodegenerative, autoimmune, oncological, and metabolic diseases. Its pipeline includes CV-01, a first-in-class Nrf2 activator; CV-02, a best-in-class S1P1-targeting treatment; CV-03, an immuno-oncology candidate; and additional programs targeting fibrosis, metabolic disorders, and tau-related neurodegenerative diseases. In addition to internal drug development, Cureverse pursues licensing, co-development, and technology transfer opportunities with domestic and international pharmaceutical companies. The company's revenue is generated primarily through the development and commercialization of proprietary drug candidates, as well as potential licensing-out agreements, joint development partnerships, technology transfers, and strategic collaborations with pharmaceutical companies. The company actively pursues business development opportunities around its drug discovery platform and pipeline assets. The company plans to advance its clinical pipeline, particularly its neurodegenerative and autoimmune disease programs, while expanding licensing and co-development opportunities with global pharmaceutical partners.
Who invested in CUREVERSE
7 investors across 1 round
See all investors in CUREVERSE
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 18, 2025
Amount
$17M
Investors
Questions about CUREVERSE
Who invested in CUREVERSE?
CUREVERSE has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CUREVERSE raised?
CUREVERSE has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did CUREVERSE last raise money?
CUREVERSE's most recent round on record is a Series B, in Jan 2025.
What does CUREVERSE do?
Based in Seoul, South Korea, CUREVERSE Inc.
Where is CUREVERSE headquartered?
CUREVERSE is headquartered in Seoul, South Korea.
Which VCs invest in companies like CUREVERSE?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at CUREVERSE's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CUREVERSE? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.